期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤治疗现状及前景 被引量：14

下载PDF
导出
摘要 多发性骨髓瘤(MM)是血液系统发病率第二的肿瘤。过去10年里,包含沙利度胺、硼替佐米、雷利度胺等药物新的联合化疗方案的应用,使得MM患者的缓解率、无进展生存期(PFS)及总生存期(OS)较长春新碱+阿霉素+地塞米松(VAD)、马法兰+泼尼松(MP)传统方案明显提高。自体造血干细胞移植(ASCT)技术的成熟、肿瘤抗原疫苗及细胞过继免疫等免疫治疗的应用,进一步降低患者复发率,明显改善预后。关于去乙酰化酶抑制剂等新型药物的探索及研究也取得突破性进展,显现出现良好的前景。现就近年来在MM的治疗中取得的进展综述如下。
作者 马李洁 李莉娟 张连生
机构地区 兰州大学第二医院血液科
出处 《临床荟萃》 CAS 2015年第4期476-480,共5页 Clinical Focus
基金 国家自然科学基金资助项目(81372533)
关键词 多发性骨髓瘤 抗肿瘤联合化疗方案 造血干细胞移植 免疫治疗
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1Stewart AK,Richardson PG. San-Miguel JF. How I treatmultiple myeloma in younger patients [J]. Blood, 2009,114(27):5436-5443.
  • 2Kortiim KM, Engelhardt M, Rasche L, et al. [ Multiplemyeloma][J], Internist (Berl) , 2013 ,54(8) : 963-977.
  • 3刘竹珍,李广伦,杨颉,崔中光.不同方案治疗多发性骨髓瘤患者血管内皮细胞功能的变化[J].临床荟萃,2014,29(2):155-158. 被引量：5
  • 4Engelhardt M, Terpos E, Kleber M, et al. EuropeanMyeloma Network recommendations on the evaluation andtreatment of newly diagnosed patients with multiple myeloma[J]. Haematologica,2014,99(2) :232-242.
  • 5Sonneveld P, Goldschmidt H,Rosinol L,et al. Bortezomib-Based Versus Nonbortezomib-Based Induction TreatmentBefore Autologous Stem-Cell Transplantation in Patients WithPreviously Untreated Multiple Myeloma: A Meta-Analysis ofPhase HI Randomized > Controlled Trials [J]. J Clin. Oncol,2013,31(26):3279-3287.
  • 6Zonder JA, Crowley J. Hussein MA, et al. Lenalidomide andhigh-dose dexamethasone compared with dexamethasone asinitial therapy for multiple myeloma: a randomized SouthwestOncology Group trial (S0232) [J], Blood, 2010, 116 (26):5838-5841.
  • 7Rajkumar SV,Jacobus S,Callander NS,et al. Lenalidomideplus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosedmultiple myeloma: an open-label randomised controlled trial[J]. Lancet Oncol, 2010,11(1) :29-37.
  • 8Fayers PM, Palumbo A, Hulin C,et al. Thalidomide forpreviously untreated elderly patients with multiple myeloma*meta-analysis of 1685 individual patient data from 6randomized clinical trials[J]. Blood,2011,118(5) : 1239-1247.
  • 9SanMiguel JF,Schlag R,Khuageva NK’et al. Bortezomib plusMelphalan and Prednisone for Initial Treatment of MultipleMyeloma[J]. N Engl J Med, 2008,359(9),906-917.
  • 10Boccadoro M, Cavallo F, Gay F. et al. Melphalan /prednisone/ lenalidomide (MPR) versus high-dose melphalanand autologous transplantation ( MEL200) plus lenalidomidemaintenance or no maintenance in newly diagnosed multiplemyeloma (MM) patients[J]. J Clin Oncol, 2013f 31 (suppl):8509.

二级参考文献17

  • 1张之南.沈悌.血液病疗效与诊断标准[M].2版.北京:科学出版社,1998:373-379.
  • 2Podar K,Anderson KC.The pathophysiologic role of VEGF in hematologic malignancies therapeutic implications[J].Blood,2005,105(4):1383-1395.
  • 3Zangari M,Anaissie E,Barlogie B,et al.Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy[J].Blood,2001,98(5):1614-1615.
  • 4Zangari M,Barlogie B,Anaissie E,et al.Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy:effects of prophylactic and therapeutic anticoagulation[J].Br J Haematol,2004,126(5):715-721.
  • 5Verheul HM,Jorna AS,Hoekman K,et al.Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets[J].Blood,2000,96(13):4216-4221.
  • 6Palumbo A,Facon T,Sonneveld P,et al.Thalidomide for treatment of multiple myeloma:10 years later[J].Blood,2008,111(8):3968-3977.
  • 7Strukova S.Blood coagulation-dependent inflammation.Coagulation-dependent inflammation and inflammation -dependent thrombosis[J].Front Biosci,2006,11:59-80.
  • 8Auwerda JJ,Sonnevele P,de Maat MP,et al.Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma[J].Haematologica,2007,92(2):279-280.
  • 9Minnema MC,Fijnheer R,de Groot PG,et al.Extremely high levels of von Willebrand factor antigen and of procoagulant factor Ⅷ found in multiple myeloma patients are associated with activity status but not with thalidomide treatment[J].J Thromb Haemost,2003,1(3):445-449.
  • 10Rajkumar SV,Jacobus S,Callander NS,et al.Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma:an open-label randomized controlled trail[J].Lancet Oncol,2010,11(1):29-37.

共引文献4

同被引文献99

  • 1朱明霞,成娟.中西医结合方案治疗老年多发性骨髓瘤的应用价值[J].中国老年学杂志,2014,34(6):1521-1522. 被引量：2
  • 2黄顺玲,戴水奇,张雪红,喻友军,谭妹莲,易长庚.湖南省酒精性肝病流行病学调查概况[J].中国医师杂志,2005,7(3):426-427. 被引量：58
  • 3谢英华,刘立根,高武,赵莉敏,韩曦瑶.以黄疸为首发表现的多发性骨髓瘤一例[J].诊断学理论与实践,2006,5(1):68-68. 被引量：4
  • 4邱录贵.多发性骨髓瘤的发病与国人特点[J].中国实用内科杂志：临床前沿版,2006,26(6):886-888. 被引量：52
  • 5Raab MS, Podar K, Breitkreutz I, et al , Multiple myeloma [J]. Lancet, 2009, 374(9686): 324-339.
  • 6Niesvizky R, Jayabalan DS, Christos PJ, et al .BIRD (Biaxin [ clarithromycin ~/Revlimid E lenalidomide ~/dexamethasone ) combination therapy results in high complete- and overall-re- sponse rates in treatment-naive symptomatic multiple myelo- ma[J]. Blood, 2008, 111(3) : 1101-1109.
  • 7Hanahan D. Less is more, regularly: metronomic dosing of eytotoxic drugs can target tumor angiogenesis in mice[J]. J Clin Invest, 2000, 105(8) : 1045-1047.
  • 8Zhang Y, Liu H, Chen X, et al . Modified bortezomib, adri- amyein and dexamethasone (PAD) regimen in advanced mulh tiple myeloma[J]. Pathol Oncol Res, 2014, 20(4) = 987-995.
  • 9Papanikolaou X, Szymonifka J, Rosenthal A, et al. Metro- nomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma ~ J ~. Haematologica, 2013, 98(7) : 1147-1153.
  • 10de Weerdt O,van de Donk NW, Veth G, et al . Continuous low-dose cyclophosphamide - prednisone is effective and well tolerated in patients with advanced multiple myeloma[J]. Neth J Med, 2001,59(2):50-56.

引证文献14

二级引证文献30

临床荟萃
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部